CGTX · Cognition Therapeutics Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $37.19M | $41.68M | $37.20M | $30.32M | $12.89M |
| SG&A | $10.61M | $12.29M | $13.53M | $13.23M | $4.52M |
| Total Operating Expenses | $47.80M | $53.97M | $50.72M | $43.55M | $17.41M |
| D&A | $36.0K | $107.0K | $96.0K | $83.0K | $98.0K |
| Operating Income | ($47.80M) | ($53.97M) | ($50.72M) | ($43.55M) | ($17.41M) |
| Interest Expense | - | - | - | - | $1.76M |
| Income Tax | $0 | $0 | $0 | $0 | - |
| Net Income | ($23.49M) | ($33.97M) | ($25.79M) | ($21.40M) | ($7.84M) |
| EPS - Basic | ($0.32) | ($0.86) | ($0.86) | ($0.91) | ($23.76) |
| EPS - Diluted | ($0.32) | ($0.86) | ($0.86) | ($0.91) | ($23.76) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $36.81M | $25.01M | $29.92M | $41.56M | $54.72M |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $1.12M | $1.98M | $3.69M | $3.22M | $4.17M |
| Current Assets | $47.99M | $29.55M | $34.22M | $47.65M | $58.99M |
| Total Assets | $48.39M | $30.23M | $35.16M | $50.42M | $59.14M |
| Current Liabilities | $13.92M | $11.14M | $10.17M | $7.79M | $7.86M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $14.12M | $11.48M | $10.69M | $10.18M | $7.86M |
| Stockholders' Equity | $34.27M | $18.75M | $24.47M | $40.25M | $51.27M |
| Retained Earnings | ($198.65M) | ($175.16M) | ($141.19M) | ($115.40M) | ($94.00M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($24.59M) | ($28.47M) | ($16.02M) | ($18.53M) | ($3.43M) |
| Investing Cash Flow | $9.0K | ($4.0K) | ($147.0K) | ($171.0K) | ($10.0K) |
| Financing Cash Flow | $36.57M | $23.57M | $4.52M | $5.55M | $5.76M |
| CapEx | - | $4.0K | $147.0K | $171.0K | $10.0K |
| Free Cash Flow | - | ($28.48M) | ($16.16M) | ($18.70M) | ($3.44M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - |
| FCF / Net income | - | 0.84 | 0.63 | 0.87 | 0.44 |
| R&D / Revenue | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -48.5% | -112.4% | -73.3% | -42.4% | -13.3% |
| Return on equity | -68.5% | -181.2% | -105.4% | -53.2% | -15.3% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 3.45 | 2.65 | 3.37 | 6.11 | 7.50 |
| Quick ratio | 3.45 | 2.65 | 3.37 | 6.11 | 7.50 |
| Cash ratio | 2.64 | 2.24 | 2.94 | 5.33 | 6.96 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | - | -9.9x |
| Equity multiplier | 1.41 | 1.61 | 1.44 | 1.25 | 1.15 |
| Liabilities / Assets | 0.29 | 0.38 | 0.30 | 0.20 | 0.13 |
| Efficiency | |||||
| Asset turnover | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 2.9x | 1.5x | 2.3x | 1.2x | 0.1x |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | 11.4% | -6.4% | -16.5% | -150.2% | - |
| Net income growth (YoY) | 30.9% | -31.7% | -20.5% | -173.0% | - |
| EPS growth (YoY) | 62.8% | 0.0% | 5.5% | 96.2% | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | - | -76.2% | 13.6% | -443.2% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | 82.8% | -23.4% | -39.2% | -21.5% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing COGNITION THERAPEUTICS INC against the 5 most active filers in the same SIC group.